Life sciences company Hikal has opened a High Potency Active Pharmaceutical Ingredient (HPAPI) laboratory at its Research and Technology Innovation Centre in Pune.
This new facility enhances Hikal’s Contract Development and Manufacturing Organisation (CDMO) capabilities, enabling the company to develop and supply highly potent compounds for the global pharmaceutical industry. The lab is specifically designed to support the development of complex oncology and specialty molecules. According to Sameer Hiremath, vice chairman and managing director of Hikal, this addition positions the company well to meet the increasing demand for potent molecule development.
This addition positions the company well to meet the increasing demand for potent molecule development, said Sameer Hiremath, vice chairman and managing director of Hikal.
Hikal partners with the pharmaceutical, animal health, and specialty chemicals industries, providing end-to-end solutions for the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Active Ingredients (AIs). The company supplies active ingredients, intermediates, and biocides to customers across the global life sciences sector.
In addition to the new HPAPI lab, Hikal has a validation lab, a process safety lab, a solid-state lab, a flow chemistry lab, and instrumentation and synthesis laboratories. This integrated innovation ecosystem at the Pune site supports the transition of projects from early-phase studies to commercial manufacturing, covering production scales from milligrams to batches exceeding 100 kilograms in the pilot plant.
Alongside the new HPAPI laboratory, the Pune innovation centre is equipped with a validation lab, a process safety lab, a solid-state lab, a flow chemistry lab, as well as instrumentation and synthesis laboratories. This integrated R&D ecosystem enables transition of projects from early-phase studies to full-scale commercial manufacturing, with capabilities ranging from milligram quantities to pilot plant batches exceeding 100 kgs.